Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNTech SEBSP:B1NT34 +17.63%49 EV-to-OCF is 12.73 as of Aug. 20, 2026, which is 1199% above its 10-year median of 0.98. GuruFocus rates BSP:B1NT34 with a GF Score™ of 49/100 and a GF Value™ of R$26.97 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,408 Biotechnology companies, BioNTech SE ranks worse than 81.61% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioNTech SE's Enterprise Value is R$56,113 Mil.
BioNTech SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was R$4,408 Mil. Therefore, BioNTech SE's EV-to-OCF for today is 12.73.
The historical rank and industry rank for BioNTech SE's EV-to-OCF or its related term are showing as below:
BSP:B1NT34'
s EV-to-OCF Range Over the Past 10 Years
Min: -18387.86 Med: 0.98 Max: 62.06
Current: 8.25
During the past 10 years, the highest EV-to-OCF of BioNTech SE was 62.06. The lowest was -18387.86. And the median was 0.98.
BSP:B1NT34's EV-to-OCF is ranked worse than 81.61% of 1408
companies
in the Biotechnology industry
Industry Median: -3.66
vs BSP:B1NT34: 8.25
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioNTech SE's PE Ratio (TTM) for today is calculated as:
BioNTech SE's share price for today is R$35.57.
BioNTech SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-2.535.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioNTech SE EV-to-OCF Related Terms
BioNTech SE EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BioNTech SE's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:B1NT34 vs INSM, INCY, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, BioNTech SE's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioNTech SE's EV-to-OCF falls into.
BioNTech SE's current Enterprise Value is R$56,113 Mil.
BioNTech SE's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$4,408 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BSP:B1NT34) has a EV-to-OCF of 12.73 as of Aug. 20, 2026. This is 1199% above median its historical median of 0.98. According to the industry distribution chart, BioNTech SE ranks #1149 out of 1408 companies in the Biotechnology industry, placing it in the top 81.6%.
Is BioNTech SE's EV-to-OCF too high?
BioNTech SE's current EV-to-OCF of 12.73 is 1199% above median its 10-year median of 0.98. Based on the distribution chart, BioNTech SE ranks #1149 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioNTech SE has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's EV-to-OCF compare to INSM and INCY?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #1149 out of 1408 companies for EV-to-OCF. This places BioNTech SE in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. BioNTech SE's current EV-to-OCF is 12.73, which is 1199% above median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BSP:B1NT34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$26.97, compared to a current price of R$35.57 — trading 31.9% above its estimated fair value. The current EV-to-OCF is 12.73, which is 1199% above median its 10-year median of 0.98. BioNTech SE's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioNTech SE (BSP:B1NT34), the current EV-to-OCF is 12.73 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BSP:B1NT34) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of R$35.57 is trading 31.9% above its estimated GF Value™ of R$26.97.
GuruFocus considers BioNTech SE to be Significantly Overvalued.
Key valuation signals for BSP:B1NT34:
EV-to-OCF: 12.73 (1199% above median its 10-year median of 0.98)
GF Value™: R$26.97 vs. price of R$35.57 (31.9% above fair value)
No single metric tells the full story. See the BSP:B1NT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
49GF Score
Get the complete analysis for BSP:B1NT34
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:B1NT34 has been successfully added to your 
